Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The sense strand is broken down as the short dsRNA unwinds. With various protein components, the antisense strand forms the RNA-induced silencing complex (RISC). The target gene's mRNA is specifically complementary to the antisense strand that RISC retains. The target gene's mRNA can be cut and degraded by the nuclease activity of RISC, which can also stop the target gene from being expressed. Inhibition of mRNA translation is the result of incomplete complementarity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75255 | AB-729 sodium | 2826248-50-2 | AB-729 sodium is an siRNA that can inhibit viral replication and reduces HBV (hepatitis B virus) antigen through RNA interference (RNAi). |
|
|
V77237 | AS-Patisiran | AS-Patisiran is the antisense strand of Patisiran. | |
|
|
V88319 | Asvasiran | 870094-26-1 | Asvasiran is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. |
|
|
V88320 | Asvasiran sodium | 1386946-83-3 | Asvasiran sodium is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. |
|
|
V75257 | ATU027 | 1415935-22-6 | ATU027 is an siRNA that silences PKN3 expression in vascular endothelium. |
|
|
V78286 | ATU027 sodium | ATU027 sodium is an siRNA that silences PKN3 expression in vascular endothelium. | |
|
|
V71321 | Bamosiran (SYL040012) | 1337968-84-9 | Bamosiran is an siRNA targeting β-adrenergic receptor 2, used to reduce intraocular pressure |
|
|
V78343 | Bamosiran sodium (SYL040012 sodium) | Bamosiran sodium is an siRNA targeting β-adrenergic receptor 2, used to reduce intraocular pressure | |
|
|
V75256 | Cimdelirsen (ISIS 766720; IONIS-GHR-LRx) | 2131025-82-4 | Cimdelirsen is a liver-targeted antisense oligonucleotide that reduces growth hormone receptor (GHr) synthesis, thereby inhibiting the harmful effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor in patients with acromegaly. |
|
|
V75254 | Cimdelirsen sodium (ISIS 766720 sodium; IONIS-GHR-LRx sodium) | 2131025-83-5 | Cimdelirsen (sodium) is a liver-targeted antisense oligonucleotide that reduces growth hormone receptor (GHr) synthesis, thereby inhibiting the deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin in patients with acromegaly. |
|
|
V79284 | Elebsiran sodium (VIR-2218 sodium) | Elebsiran sodium is an siRNA against HBV (hepatitis B virus) and hepatitis D virus (HDV) infection. | |
|
|
V75253 | Fazirsiran (ARO-AAT) | 2175009-08-0 | Fazirsiran (ARO-AAT) is a second-generation RNA interference (RNAi) active molecule. |
|
|
V90312 | Fazirsiran sodium | 2175009-09-1 | Fazirsiran sodium is a second generation RNA interference (RNAi) active molecule. |
|
V73137 | Fitusiran (ALN-AT3SC; SAR439774) | 1499251-18-1 | Fitusiran (ALN-AT3SC) is a small interfering RNA that specifically targets antithrombin (AT) messenger RNA to reduce AT production in the liver. |
|
|
V51385 | GalNAc unconjugated/naked Fitusiran | GalNAc unconjugated/naked Fitusiran is a small interfering RNA without conjugated GalNAc that specifically targets antithrombin (AT) messenger RNA to reduce AT production in the liver. | |
|
|
V87431 | GalNAc unconjugated/naked Fitusiran sodium | GalNAc unconjugated/naked Fitusiran (sodium) is a GalNAc-unconjugated small interfering RNA that specifically targets antithrombin (AT) messenger RNA to reduce AT production in the liver. | |
|
|
V51386 | GalNAc unconjugated/naked Inclisiran | GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) molecule without conjugated GalNAc that can inhibit the transcription of PCSK-9. | |
|
|
V88923 | Givosiran sodium | Givosiran sodium is a small interfering RNA that targets the hepatic aminocellulose synthase 1 (ALAS1) messenger RNA. | |
|
|
V83977 | Inclisiran sodium (ALN-PCSsc sodium) | ||
|
|
V75258 | Lumasiran sodium | 1834612-06-4 | Lumasiran sodium is an investigational RNA interference (RNAi) agent that reduces hepatic oxalate production by targeting glycolate oxidase. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
